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Summary
Background Few genetic studies that focus on moderate-to-severe asthma exist. We aimed to identity novel genetic 
variants associated with moderate-to-severe asthma, see whether previously identified genetic variants for all types of 
asthma contribute to moderate-to-severe asthma, and provide novel mechanistic insights using expression analyses 
in patients with asthma.
Methods In this genome-wide association study, we used a two-stage case-control design. In stage 1, we genotyped 
patient-level data from two UK cohorts (the Genetics of Asthma Severity and Phenotypes [GASP] initiative and the 
Unbiased BIOmarkers in PREDiction of respiratory disease outcomes [U-BIOPRED] project) and used data from 
the UK Biobank to collect patient-level genomic data for cases and controls of European ancestry in a 1:5 ratio. 
Cases were defined as having moderate-to-severe asthma if they were taking appropriate medication or had been 
diagnosed by a doctor. Controls were defined as not having asthma, rhinitis, eczema, allergy, emphysema, or 
chronic bronchitis as diagnosed by a doctor. For stage 2, an independent cohort of cases and controls (1:5) was 
selected from the UK Biobank only, with no overlap with stage 1 samples. In stage 1 we undertook a genome-wide 
association study of moderate-to-severe asthma, and in stage 2 we followed up independent variants that reached 
the significance threshold of p less than 1 × 10–⁶ in stage 1. We set genome-wide significance at p less than 5 × 10–⁸. 
For novel signals, we investigated their effect on all types of asthma (mild, moderate, and severe). For all 
signals meeting genome-wide significance, we investigated their effect on gene expression in patients with asthma 
and controls.
Findings We included 5135 cases and 25 675 controls for stage 1, and 5414 cases and 21 471 controls for stage 2. We 
identified 24 genome-wide significant signals of association with moderate-to-severe asthma, including several 
signals in innate or adaptive immune-response genes. Three novel signals were identified: rs10905284 in GATA3 
(coded allele A, odds ratio [OR] 0·90, 95% CI 0·88–0·93; p=1·76 × 10–¹⁰), rs11603634 in the MUC5AC region (coded 
allele G, OR 1·09, 1·06–1·12; p=2·32 × 10–⁸), and rs560026225 near KIAA1109 (coded allele GATT, OR 1·12, 1·08–1·16; 
p=3·06 × 10–⁹). The MUC5AC signal was not associated with asthma when analyses included mild asthma. The 
rs11603634 G allele was associated with increased expression of MUC5AC mRNA in bronchial epithelial brush 
samples via proxy SNP rs11602802; (p=2·50 × 10–⁵) and MUC5AC mRNA was increased in bronchial epithelial 
samples from patients with severe asthma (in two independent analyses, p=0·039 and p=0·022).
Interpretation We found substantial shared genetic architecture between mild and moderate-to-severe asthma. We 
also report for the first time genetic variants associated with the risk of developing moderate-to-severe asthma that 
regulate mucin production. Finally, we identify candidate causal genes in these loci and provide increased insight into 
this difficult to treat population.
Funding Asthma UK, AirPROM, U-BIOPRED, UK Medical Research Council, and Rosetrees Trust.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Asthma is a common disease and was identified as the 
most prevalent chronic respiratory disease in the Global 
Burden of Diseases, Injuries, and Risk Factors Study 
(GBD) 2015.1,2 10–15% of individuals with asthma have 
severe asthma and substantial unmet clinical needs, with 
symptoms including debilitating breathlessness, associ­
ated frequent exacer bations, and increased hospital 
admissions despite the high use of medicines.3 Both 
genetic and environ mental factors contribute to disease 
risk, with genetic factors thought to account for 35–95% of 
the susceptibility to develop asthma.4 Previous genome­
wide association studies5–20 have identified 38 regions of 
association with asthma, including signals in or near 
PEX14, IL6R, PYHIN1 (African American individuals 
only), ADAMTS4, CD247, TNFSF18, DENND1B, ADORA1, 
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ID2, IL1RL1/IL18R1, D2HGDH, LPP, TLR1, USP38 
(Japanese individuals only), PDE4D, TSLP/WDR36, 
RAD50/IL13, NDFIP1, GPX5, HLA-C/NOTCH4/HLA-
DRB1/HLA-DQA1, GRM4, BACH2, CDHR3, SLC30A8 
(Japanese individuals only), ZBTB10, IL33, EQTN, GATA3, 
LRRC32, IKZF4, STAT6, RAD51B, RORA, SMAD3, 
CLEC16A, ERBB2/GSDMB/ORMDL3, ZNF652, and 
IL2RB. Asthma signals sub stantially overlap with signals 
reported in genome­wide association studies of self­
reported allergy and allergic sensitisation—eg, TLR1, 
WDR36, IL1RL1, SMAD3, STAT6, C11orf30 (EMSY), 
IL1RL1, and TLR1.21,22 In a 2018 genome­wide association 
study of allergic disease and asthma,23 the authors showed 
a genetic correlation between asthma and allergic disease 
with evidence of specific loci being unique to asthma—
eg, ORMDL3.
The concept of shared genetic origins between different 
allergic diseases has been tested in a large genome­wide 
association study24 with 180 129 cases (asthma, allergic 
rhinitis, or atopic dermatitis) and 180 709 controls. The 
study identified 99 genetic susceptibility loci, including 
136 independent signals implicating genes involved 
predominantly in immune function, with only six signals 
showing some disease specificity—eg, ORMDL3 specific 
for asthma.
In the first genome­wide association study in severe or 
difficult to treat asthma,25 which used the Epidemiology 
and Natural History of Asthma: Outcomes and Treatment 
Regimes (TENOR) cohort, associations with known 
asthma loci were found—eg, with single nucleotide 
polymorphisms (SNPs) in the RAD50/IL13 and HLA-DR/
HLA-DQ regions. Similarly, the Asthma UK Genetics of 
Severe Asthma (AUGOSA) study19 of moderate­to­severe 
asthma replicated the known 17q21 association at 
ORMDL3/GSDMB/ZPB2. Neither study identified any 
new signals that met genome­wide significance, potentially 
because the number of cases was small. Therefore, we 
aimed to complete a large genome­wide association study 
of moderate­to­severe asthma to address three specific 
objectives: first, we aimed to identify novel signals 
predicting disease risk for moderate­to­severe asthma 
(as opposed to mild asthma); second, we wanted to see 
whether asthma signals that have been previously 
described were specifically associated with moderate­to­
severe asthma; and finally, we aimed to translate genetic 
findings into disease mechanisms via initial functional 
studies using the Unbiased BIOmarkers in PREDiction of 
Respiratory Disease Outcomes (U­BIOPRED) integrated 
asthma patient genomics resource,26 which might in turn 
identify new targets for therapeutic intervention.
Methods
Study design and participants
In this genome­wide association study, we used a 
two­stage design to identify novel and significant genome­
wide associations that confer susceptibility to moderate­
to­severe asthma. We used a two­stage case­control 
design, with variants that showed suggestive association 
(p<1 × 10–⁶) in stage 1 tested in stage 2 and then meta­
analysed across the two stages to maximise power. 
Research in context
Evidence before this study
We searched the National Human Genome Research 
Institute-European Bioinformatic Institute Catalog of 
published genome-wide association studies from database 
inception to January, 2018, for studies that tested the 
association between genetic variants and asthma using the 
search term “asthma”, and manually searched the findings to 
identify studies that used a diagnosis of asthma to define cases. 
We examined the original publications and included studies 
with more than 500 cases and 500 controls and we considered 
signals of relevance to be those that met genome-wide 
significance (p<5 × 10⁻⁸). These previous studies reported 
38 regions associated, at genome-wide significance, with 
susceptibility to develop asthma, providing novel insight into 
disease biology. To date, only two genome-wide association 
studies have specifically investigated moderate-to-severe 
asthma; however, the power of these studies was restricted by 
the number of cases included (<1000).
Added value of this study
To our knowledge, this is the largest genetic study of 
moderate-to-severe asthma to date. We identified three novel 
genome-wide significant genetic associations that imply 
MUC5AC, GATA3, and KIAA1109 have an association with 
susceptibility to the development of moderate-to-severe 
asthma. Altered expression of the pathogenic mucin MUC5AC 
potentially contributes to mucus plugging and airway 
obstruction, GATA3 is a transcription factor linked to the T-cell 
response in asthma and eosinophilia, and the KIAA1109 locus 
has previously been associated with allergic sensitisation. We 
also describe and further characterise the contribution of 
21 previously described asthma signals to this phenotype, 
and identify potential candidate causal genes.
Implications of all the available evidence
Identification of genetic associations with variants in multiple 
genes of the innate or adaptive immune (type 2 inflammation) 
pathways suggest that targeting this pathway could be a 
therapeutic opportunity in moderate-to-severe asthma. The 
association identified between variants in the MUC5AC locus 
adds to evidence of alterations in the airway epithelium and 
mucin dysregulation in more severe forms of asthma, and 
potentially supports specific targeting of MUC5AC expression 
and induction in severe asthma. Identification of the GATA3 and 
KIAA1109 signals further extend the data that genetic variants 
in these regions are associated with asthma, potentially via 
eosinophilia and allergic sensitisation, two drivers of asthma 
that are also important in moderate-to-severe disease.
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For stage 1, we selected individuals of European 
ancestry with moderate­to­severe asthma who had been 
recruited from primary and secondary care settings 
across the UK as part of the Genetics of Asthma Severity 
and Phenotypes (GASP) initiative, with additional cases 
included from the U­BIOPRED asthma cohort26 and the 
UK Biobank May, 2015,27,28 genetic data release (appendix). 
Genotyped data were assessed for quality control (details 
are in the appendix). From GASP and U­BIOPRED, we 
identified patients with moderate­to­severe asthma by 
assessing clinical records that indicated that a patient was 
taking medication required for patients defined as having 
moderate­to­severe asthma according to the British 
Thoracic Society (BTS) 2014 guidelines.29 From the UK 
Biobank, cases of moderate­to­severe asthma were 
defined as having asthma diagnosed by a doctor, taking 
medi cation for asthma, no diagnosis of emphysema or 
chronic bronchitis by a doctor, and meeting the definition 
of moderate­to­severe asthma by BTS criteria. Therefore, 
cases were selected from individuals for whom medi­
cation infor mation was available and who met BTS 
stage 3–5 criteria—ie, for stage 3, taking a long­acting 
β₂ agonist plus inhaled corticosteroid; stage 4, taking 
higher dose inhaled corti costeroids than stage 3 patients, 
and addition of a fourth drug (eg, leukotriene receptor 
antagonist, theophylline); and stage 5, taking oral corti­
costeroid or omalizumab, or both. A complete list of 
medications used to identify patients with moderate­to­
severe asthma is in the appendix. Controls for stage 1 
were identified from the UK Biobank by taking the 
remaining subjects for whom genotyped data were 
available that passed quality control and excluding 
individuals with asthma, rhinitis, eczema, allergy, 
emphysema, or chronic bronchitis as diagnosed by a 
doctor, or if medication data were not available to assign 
to either the mild­moderate or moderate­severe asthma 
group. Additional controls for stage 1 were included from 
U­BIOPRED to ensure we had controls from each cohort. 
Patients in the U­BIOPRED cohort had not been screened 
for rhinitis or eczema, and so this information was not 
available for these controls at time of selection. For stage 
2, both cases and controls were selected from the UK 
Biobank May, 2017, release using the same criteria to 
define cases and controls as in stage 1. There was no 
overlap in the patients included in stage 1 and stage 2. A 
case­control ratio of 1:5 was chosen for both stages to 
balance power and computational time. Cases and 
controls were matched across age and sex strata, and in 
stage 1 across genotyping arrays. All cohorts included 
individuals with self­reported European ancestry; 
individuals of non­European ancestry were excluded to 
reduce confounding of the study by ancestry. 
UK Biobank has ethical approval from the UK National 
Health Service (NHS) National Research Ethics Service 
(Ref 11/NW/0382). All other studies were approved by an 
appropriate ethics committee. Informed consent was 
obtained from all participants.
Procedures
In stage 1, cases and controls were genotyped using the 
Affymetrix Axiom (Affymetrx, Santa Clara, CA, USA) UK 
BiLEVE array30 and the later­generation Affymetrix 
Axiom UK Biobank array, which are 95% identical in 
content. In stage 2, only the later­generation Affymetrix 
Axiom UK Biobank array was used. If the sentinel SNP 
from stage 1 was not available in stage 2, a proxy was 
chosen with the highest linkage disequilibrium to the 
sentinel SNP. Genotyping and imputation procedures 
are described in the appendix. After imputation using 
UK10K Project31 and 1000 Genomes Project Phase 332 
reference panels, 33 771 858 SNPs were available for 
association testing in stage 1 (appendix).
Statistical analysis
Descriptive statistics of baseline characteristics were 
compared using a χ² test to check for imbalances in 
comorbidities, smoking, and oral corticosteroid use 
between cases in stage 1 and 2. Our sample sizes were 
determined by the number of moderate­to­severe cases 
in each cohort for each stage. We then collected data for 
an excess of potenial controls and used a ratio of 1:5 cases 
to controls to maximise the power of our study.
For stage 1, we used a logistic model of association to 
determine genome­wide associations for susceptibility 
to moderate­to­severe asthma and assumed an additive 
genetic model of asthma status with imputed genotype 
dose fitted (effect allele count continuous over the range 
0–2 to reflect uncertainty in genotype imputation) using 
SNPTEST version 2.5,33 adjusted for ancestry using the 
first ten principal components of genotypic variance 
derived by EIGENSOFT 6.1.4. In stage 1, we used 
conditional analyses (Genome­wide Complex Trait 
Analysis version 1.26.034) to identify additional independ­
ent signals in the same loci (passing the same threshold 
of p<1× 10–⁶ as for the unconditional analysis) and we did 
a sensitivity analysis to check for array effects. In stage 2, 
we followed up independent variants that reached the 
p value significance threshold of less than 1 × 10–⁶ in 
stage 1 association testing. 
Variants with p<1 × 10–⁶ in stage 1 were then meta­
analysed across stage 1 and stage 2 using inverse­
variance weighted meta­analyses. Variants with the 
same direction of effect in stages 1 and 2, with a 
genome­wide significant association (ie, p<5 × 10–⁸) in 
the meta­analyses of stages 1 and 2 and a p value of less 
than 0·05 in stage 2, were included in further analyses. 
We used a Bonferroni correction for the number of 
putative novel signals as the threshold for independent 
replication in stage 2. We controlled for age and sex 
by selecting cases and controls with similar age 
and sex distributions. Ancestry was controlled by 
selecting European samples and including ten principal 
components as covariates. To avoid missing data, we 
only included samples with complete phenotype, age, 
sex and covariate data.
See Online for appendix
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Because we excluded patients with allergic disease 
from the controls in stage 1 and 2, we could potentially 
have inflated shared genetic signals associated with 
allergic comorbidities in the asthma population. Hence, 
we also did a sensitivity analysis that included stage 2 
cases and controls including individuals with rhinitis, 
eczema, and allergy.
To investigate whether novel variants we identified as 
associated with moderate­to­severe asthma showed an 
association with susceptibility to all types of asthma (mild, 
moderate, and severe), we interrogated a large genome­
wide association study of asthma,5 which included 
28 399 cases of self­reported asthma and 128 843 controls. 
We also investigated SNPs previously associated with 
asthma5–20 and allergic diseases23,24 at genome­wide 
significance (p<5 × 10–⁸) in our stage 1 dataset.
For all signals we determined to have a genome­wide 
significant association with moderate­to­severe asthma, 
we investigated the lead SNP (and SNPs in linkage 
disequilibrium—ie, r²>0·4) for association with mRNA 
levels in cells and tissues using expression quantitative 
loci (eQTL) datasets. For lung tissue we used an eQTL 
database with data for 1110 subjects,35 and for blood cells 
we used an eQTL database with data for 5311 subjects,36 
27 082 controls including those 
with rhinitis, eczema, or 
allergy (sensitivity 
analyses) 
156 460 samples genotyped
2976 from GASP
755 from U-BIOPRED
152 729 from UK Biobank (May, 2015)
87 875 samples imputed
 1859 from GASP
 360 from U-BIOPRED
 85 656 from UK Biobank (May, 2015)
5135 cases with moderate-to-
 severe asthma
1858 from GASP
281 from U-BIOPRED
2996 from UK Biobank
80 704 controls
0 from GASP
75 from U-BIOPRED
80 629 from UK Biobank
25 675 controls
0 from GASP
75 from U-BIOPRED
25 600 from UK Biobank
68 585 excluded
 1117 from GASP
688 did not pass control
429 did not meet case or control 
 criteria 
395 from U-BIOPRED
329 did not pass quality control
 66 did not meet case or control
 criteria
67 073 from UK Biobank
59 937 did not meet case or control
 criteria
 6656 not of European ancestry 
480 did not pass quality control
2036 excluded because related*
 1 from GASP
 4 from U-BIOPRED
 2031 from UK Biobank
55 029 unused controls from 
UK Biobank
488 377 samples genotyped from UK Biobank 
final release (May, 2017) 
280 643 samples imputed
5414 cases with moderate-to-
 severe asthma
21 471 controls (main analysis)
207 734 excluded
 145 853 already in stage 1
 32 820 did not meet case or control criteria 
 28 093 not of European ancestry 
 968 did not pass quality control
 
 
 
28 589 excluded because related to stage 1 or 2 cases 
5611 excluded with rhinitis,
 eczema, or allergy
246 640 controls
219 558 unused
Stage 1 Stage 2
Figure 1: Quality control and sample selection
GASP=Genetics of Asthma Severity and Phenotypes. U-BIOPRED=Unbiased BIOmarkers in PREDiction of respiratory disease outcomes. *Related samples (second degree or closer) were removed; see 
appendix for more details of sample selection. 
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and we used a 10% false discovery rate for eQTLs for 
these two databases. To complement these resources, we 
used five additional U­BIOPRED eQTL datasets37–39 for 
blood (n=345), sputum (n=91), bronchial biopsy samples 
(n=84), bronchial brushing (n=117), and nasal brushing 
(n=75), and for these datasets we used a 5% false 
discovery rate (appendix). For the U­BIOPRED cohort, 
DNA from whole blood was extracted and genotyped as 
outlined and after imputation (SHAPEIT2 for pre­
phasing and IMPUTE 2, using 1000 Genome Phase 3 as 
reference panel) and quality control, 2 536 796 SNPs were 
available for association testing. Transcriptomic analysis 
was done with the Affymetrix HT HG­U133 1 PM 
GeneChip (Affymetrix, Santa Clara, Calif) on extracted 
RNA from the different samples. When the sentinel SNP 
was not available we used a proxy with the highest 
linkage disequilibrium. We considered an association 
signal meeting the designated false discovery rate for any 
dataset to be of interest.
For novel signals for which an eQTL effect was 
observed, we investigated the expression of proteins in 
human lung tissue using Protein Atlas40 to identify 
relevant airway cell types for further study. We also 
investigated mRNA levels in patients with severe asthma 
using two gene expression omnibus datasets to see if 
altered expression is a feature of these patients compared 
with patients with mild asthma, which might imply a 
mechanistic role in moderate­to­severe disease, 
(appendix). GSE4369641 includes Agilent Human GE 
4×44K V2 Gene Expression data for bronchial epithelial 
cells from 20 controls, 50 patients with mild asthma, and 
38 patients with severe asthma. GSE8980942 contains 
Affymetrix HT HG­U133+ PM GeneChip data for 
18 controls, and 14 patients with mild asthma, 13 with 
moderate asthma, and 11 with severe asthma. The 
definition of asthma severity was different between 
these studies. In GSE43696, patients with mild­to­
moderate asthma had a predicted forced expiratory 
volume in 1 s of less than 60%, with or without a 
low­to­moderate dose of inhaled corticosteroids, and 
patients with severe asthma were defined as having 
continuous use of high­dose inhaled corticosteroids or 
frequent use of oral corticosteroids, or both, with 
continuing symptoms or chronic airflow limitations. In 
GSE89809, patients with mild asthma were defined as 
taking β₂ agonists alone, those with moderate asthma as 
taking inhaled corticosteroids, and those with severe 
asthma had persistent symptoms despite taking high­
dose inhaled corticosteroids and oral corticosteroids. 
Both of these studies defined patients as having 
moderate­to­severe asthma by use of medication, and so 
comparable definitions were used between these 
genome­wide association studies and our study. Robust 
multi­array average data was extracted from these datasets 
for KIAA1109 and MUC5AC and expression was 
compared across groups (Kruskal­Wallace test).
To provide insight into the disease mechanism, 
we investigated lead SNPs (and SNPs in linkage 
Stage 1 cohort Stage 2 cohort
Cases 
(n=5135)
Controls 
(n=25 675)
Cases 
(n=5414)
Controls 
(n=21 471)
Controls for 
sensitivity analyses* 
(n=27 082)
Age, years 55 (12) 56 (8) 58 (8) 58 (8) 58 (8)
Sex
Female 3170 (61·7%) 14 626 (57·0%) 3354 (62·0%) 13 135 (61·2%) 16 816 (62·1%)
Male 1965 (38·3%) 11 049 (43·0%) 2060 (38·0%) 8336 (38·8%) 10 266 (37·9%)
FEV1, % predicted 72·4% (21·4) 91·8% (17·4) 84·5% (17·2) 93·7% (14·1) 93·9% (13·9)
FEV1/FVC 0·67 (0·12) 0·76 (0·06) 0·73 (0·09) 0·77 (0·06) 0·77 (0·06)
Smoking status
Ever smoker 2265 (44·1%) 11 913 (46·4%) 2509 (46·3%) 9479 (44·2%) 11 707 (43·2%)
Never smoker 2647 (51·6%) 13 487 (52·5%) 2787 (51·5%) 11 621 (54·1%) 14 918 (55·1%)
Unknown 223 (4·3%) 275 (1·1%) 118 (2·2%) 371 (1·7%) 457 (1·7%)
Rhinitis or eczema status
Yes 1897 (36·9%) 8† 2556 (47·2%) 0 5541 (20·5%)
No 2062 (40·2%) 25 667† 2858 (52·8%) 21 471 (100%) 21 541 (79·5%)
Unknown 1176 (22·9%) 0† 0 0 0
Oral corticosteroid use (prednisolone) 222/3710 (6·0%) NA 162/5414 (3·0%) NA NA
Data are mean (SD) or n (%), unless otherwise stated. FEV1=forced expiratory volume in 1 s. FVC=forced vital capacity. NA=not applicable. U-BIOPRED=Unbiased BIOmarkers 
in PREDiction of respiratory disease outcomes. *Including all controls with rhinitis, eczema, and allergy. †Patients in the U-BIOPRED cohort were not screened for rhinitis or 
eczema before sample selection but were subsequently found to comprise eight patients with rhinitis, eczema, or allergy.
Table 1: Baseline characteristics of stage 1 and stage 2 cohorts
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disequilibrium with r²>0·4) at the novel loci using the 
HaploReg version 4 resource43 and the deep­learning 
functional prediction resource DeepSEA.44 We used 
GRASP45 and a GWAS catalog46 to identify whether any 
variants in linkage disequilibrium with the three novel 
signals had previously been reported in genome­wide 
association studies of other diseases or quantitative 
outcomes.
Role of the funding source
The funder of the study had no role in study design, data
collection, data analysis, data interpretation, or writing of 
the report. IS and LVW had full access to all the data in 
the study and had final responsibility for the decision to 
submit for publication. 
Results
For the stage 1 analyses, after genotyping of the GASP 
and U­BIOPRED cohorts and using available data from 
the UK BioBank (May, 2015,  release), data were available 
for 5135 moderate­to­severe asthma cases, (GASP 
n=1858, U­BIOPRED n=281, and UK Biobank n=2996), 
and 25 675 controls (U­BIOPRED n=75, and UK Biobank 
n=25 600; figure 1). For the independent stage 2 cohort, 
5414 cases and 21 471 controls were selected from the UK 
Biobank (May, 2017, release) after excluding the cases 
and controls in stage 1. Baseline characteristics for the 
stage 1 and 2 cohorts are in table 1.
Cases in the stage 1 cohort had lower lung function and 
higher use of oral corticosteroids than cases in stage 2, 
suggesting a higher severity of asthma among the stage 1 
cases. Cases in the stage 1 and 2 cohorts did not differ 
significantly by the proportion who had allergic 
comorbidities (allergic rhinitis or eczema, or both; 
p=0·51) or a history of smoking (p=0·21).
In stage 1, 32 independent signals were associated (ie, 
p<1 × 10–⁶) with susceptibility to moderate­to­severe 
asthma, of which 21 additionally met genome­wide 
significance (p<5 × 10–⁸) in stage 1 alone (figure 2; 
appendix). Array sensitivity analyses did not identify any 
array effects (appendix). The 32 signals included 
independent second ary signals at the TSLP, IL13/RAD50, 
and HLA loci (appendix).
All 32 signals showing association in stage 1, including 
11 potentially novel signals (appendix), were further 
analysed in the stage 2 cohort dataset. In stage 2 
analyses, 26 signals showed consistent direction of 
effect and p values of less than 0·05 for association 
(appendix).
After meta­analyses of data from stages 1 and 2, we 
identified 25 signals that showed consistent direction 
of effect and overall genome­wide significance. After 
sensitivity analyses in stage 2, the rs61816761 (Filaggrin, 
FLG) signal was excluded because the signal was at least 
in part driven by atopy (appendix).
Of the 24 signals, after exclusion of FLG (table 2), 
three were novel for asthma (figure 3): the sentinel SNP 
rs10905284 in GATA3 (coded allele A, odds ratio [OR] 0·90, 
95% CI 0·88–0·93; p=1·76 × 10–¹⁰) and rs11603634 in the 
MUC5AC region (coded allele G, OR 1·09, 1·06–1·12; 
p=2·32 × 10–⁸). The third signal included an indel 
(rs560026225, proxy in stage 2 rs72687036) in a locus 
covering KIAA1109 (coded allele GATT, OR 1·12, 
1·08–1·16; p=3·06 × 10–⁹). rs10905284 (GATA3) is a novel 
signal for asthma independent from previously described 
signals in the GATA3 region for asthma—eg, rs10508372,15 
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Figure 2: Manhattan plot for stage 1 analyses of risk of moderate-to-severe asthma
Data are for 5135 cases with moderate-to-severe asthma and 25 675 controls assessed for 33·8 million well-imputed variants. p values have had genomic control 
applied. Red data points are signals meeting criteria for follow-up in stage 2 (p<1 × 10⁻⁶) and the dotted line indicates genome-wide significance (p<5 × 10⁻⁸). Loci are 
labelled with the nearest gene for the 24 signals meeting genome-wide significance in the meta-analysis. Quantile-quantile plot for this analysis is in the appendix.
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rs2589561,11 and rs12413578.5 Confirmed by conditional 
analyses, we identified a second signal in the GATA3 
region, rs61840192 (labelled LOC101918272 because it is 
distal from GATA3; table 2), which is in linkage 
disequilibrium with the previously described signals at 
rs12413578 (r²=0·166) and rs2589561 (r²=0·161). Both the 
KIAA1109 and GATA3 signals meet the threshold for 
independent replication based on Bonferroni correction 
threshold (p<0·005, Bonferroni correction for 11 potentially 
novel signals); however, the MUC5AC signal did not meet 
this threshold but was nominally significant (p=0·018; 
table 2) 
To identify if the novel signals for moderate­to­severe 
asthma were also associated with all asthma including 
mild disease, we checked the association results from a 
large independent genome­wide asso ciation study.5 We 
found both the KIAA1109 and GATA3 signals were 
significantly associated with all asthma, including mild 
asthma (KIAA1109 [proxy rs72687036 coded allele G]: 
OR 1·06, 95% CI 1·04–1·08; p=3·96 × 10–⁷; and GATA3 
[rs10905284, risk allele C]: OR 1·04, 1·02–1·06; 
p=2·72 × 10–⁵). No association was identified between the 
MUC5AC signal and all asthma (rs11603634, coded 
allele G: OR 1·00, 0·97–1·02; p=0·809; appendix).
In our systematic investigation of all previously 
described signals associated with asthma published to 
date (appendix),5–20 we found that 60 (75%) of 80 previously 
reported SNPs showed an association with moderate­to­
severe asthma (p<6 × 10–⁴ after Bonferroni correction), 
and a further ten (8%) SNPs showed a nominally 
significant association in our stage 1 cohort (p<0·05; 
appendix). The effect estimates (ORs) for previously 
described asthma signals in this study range from 1·08–
1·24 (appendix). Similarly, we investigated previously 
reported SNPs associated with allergic diseases in two 
large studies23,34 (appendix). Of the 136 signals identified 
in the study by Ferreira and colleagues,24 87 (64%) were 
nominally associated (p<0·05) with moderate­to­severe 
asthma, 40 (29%) signals had an association (ie, p<6 × 10–⁴ 
after Bonferroni correction). Similarly, for the 38 signals 
identified in the study by Zhu and colleagues,23 
35 (92%) were nominally associated with moderate­to­
severe asthma, with 28 (74%) signals meeting a 
Bonferroni corrected threshold.
In our eQTL analyses of the three novel signals we 
found rs11603634 (MUC5AC) was an eQTL for MUC5AC 
in bronchial epithelial brush cells (via proxy SNP 
rs11602802, r²=0·46; appendix). The rs11603634 asthma 
risk allele (G) was correlated with rs11602802 (A) allele, 
which was associated with increased levels of MUC5AC 
mRNA (figure 4). Although they did not meet the 5% 
false discovery rate, MUC5B mRNA levels showed an 
opposite association with the rs11602802 SNP (appendix). 
Similarly, the proxy SNP rs17454584 (r²=0·57) for 
rs560026225 (KIAA1109) was an eQTL for KIAA1109 in 
lung tissue with the asthma risk allele (GATT) associated 
with decreased expression of KIAA1109 (rs560026225 
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GATT allele correlated with rs17454584 G allele; figure 5). 
No significant eQTL association was observed for the 
rs10905284 (GATA3) signal. We identified significant 
eQTL associations for 16 (76%) of 21 previously reported 
asthma signals in the lungs or blood, or both (appendix). 
We identified a large number of potential candidate 
causal genes in the type 2 inflammatory pathway, 
including the following subset: adaptive and innate 
immune response genes; CD247, IL1RL1, IL18R1, TSLP, 
human leukocyte antigen genes, BACH2, IL33, and 
STAT6, and genes that might be important in airway 
structural cell homoeostasis, integrity, or function—eg, 
MUC5AC, D2HGDH, ING5, WDR36, RAD50, SLC22A5, 
SMAD3, ORMDL3, GSDMA, and GSDMB.
We found MUC5AC and KIAA1109 expression is present 
in airway epithelium and localised to the cytoplasm and 
membrane (appendix); therefore, we hypothesised that 
concen trations of MUC5AC and KIAA1109 could be 
altered in airway epithelium in patients with severe 
asthma. We found high levels of MUC5AC mRNA in 
patients with severe asthma (figure 4) but did not identify 
any differential expression of KIAA1109 in the same 
bronchial epithelial datasets (figure 5).
Using HaploReg, we identified a large number of 
potentially functional consequences of MUC5AC, 
KIAA1109, and GATA3 sentinel SNPs and SNPs in 
linkage disequilibrium (appendix). In the MUC5AC 
locus, multiple SNPs including the lead SNP 
(rs11603634) altered Fox family transcription factors 
(appendix). For the KIA1109 and GATA3 signals, many 
potentially functional changes were apparent (appendix). 
Using DeepSEA, the moderate­to­severe asthma risk 
allele (G) at the sentinel SNP rs11603634 near MUC5AC 
was predicted to result in a log₂ fold change of more 
than 1·5 in function at Forkhead Box A1 (FOXA1) and 
Forkhead Box A2 (FOXA2) binding sites in airway 
epithelium (appendix). For the rs10905284 (GATA3), the 
asthma risk allele (C; proxy rs3802597; r²=0·93) had an 
effect on upstream stimulatory factor 1 (USF1) and 2 
(USF2) binding in various cell types, including airway 
epithelium (appendix). rs560026225 (KIAA1109; proxy 
rs17389644; r²=0·57) had a functional effect on a DNase 
hypersensitivity site in human microvascular endothelial 
and human umbilical vein endothelial cell types 
(appendix).
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Figure 3: Regional association plots of novel signals KIAA1109 (A), GATA3 
(B), and MUC5AC (C) associated with moderate-to-severe asthma
Regional association plots from stage 1 analyses for the three novel signals that 
show statistically replicated association in stages 1 and 2 and met genome-wide 
significance in the meta-analyses. Significance of each single nucleotide 
polymorphism (SNP) is on the –log10 scale as a function of chromosome position 
(NCBI build 37). The sentinel SNP at each locus is shown by the blue peak, and 
data points are colour coded to show the correlations (r²) of each of the 
surrounding SNPs to the sentinel SNP. The green line indicates signals meeting 
criteria for inclusion in stage 2 (p<1 × 10⁻⁶) and the red line indicates 
genome-wide significance (p<5 × 10⁻⁸).
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GRASP and GWAS catalog analyses of the three novel 
signals, and variants in linkage disequilibrium identified 
genome­wide significant associations. The rs560026225 
(KIAA1109) asthma risk allele (GATT; allele associated 
with increased risk of moderate­to­severe asthma) was 
associated with risk of allergic sensitisation (proxy 
rs17454584, with the rs560026225 GATT allele correlated 
with rs17454584 G allele),22 the rs10905284 (GATA3) 
asthma risk allele (C) was associated with an increased 
number of eosinophils in the blood,47 and the rs11603634 
(MUC5AC) asthma risk allele (G; proxy rs4077759, 
rs11603634 G allele correlated with rs4077759 T allele) was 
associated with risk of pulmonary fibrosis (appendix).48
Discussion
To our knowledge, we present the largest genetic­
association study of moderate­to­severe asthma to date, 
with 10 549 cases and 47 146 controls, identifying 
24 signals that reach genome­wide significance in the 
meta­analysis of stages 1 and 2. 21 (88%) of 24 signals 
have previously been reported in studies that 
predominantly assessed samples from patients with mild 
asthma, suggesting a substantial shared genetic 
architecture between mild and moderate­to­severe 
asthma. Our findings suggest that additional factors 
might drive the development of more severe forms of 
asthma—eg, environmental exposures or epigenetics, 
and the presence of comorbidities. We also provide 
increased insight into the identification of candidate 
casual genes in many of these loci, including several 
genes associated with type 2 inflammation. Three signals 
we identify here have not previously been reported for 
asthma in genome­wide association studies: rs11603634 
in the MUC5AC region (coded allele G, frequency 
50·4%, risk), rs1090584 in GATA3 (coded allele A, 
frequency 57·06%, protective), and rs560026225 (coded 
allele GATT, frequency 23·60%, risk) in a locus covering 
KIAA1109. The rs11603634 signal is specific to moderate­
to­severe asthma and we identified that MUC5AC is 
increased in bronchial epithelial cells of carriers of the 
risk allele, with MUC5B being decreased in carriers of 
the risk allele, albeit not reaching our significance 
threshold. This genotype specific expression might be 
caused by alterations in FOXA transcription activity. For 
the GATA3 and KIAA1109 signals we saw an association 
with all asthma, while GATA3 has been previously 
reported to be associated with increased concentrations 
of blood eosinophil47 and KIAA1109 has been reported as 
being associated with self­reported allergy.21 Therefore, 
we provide additional insight into the genetic architecture 
of moderate­to­severe asthma and we report the first 
evidence that genetic variants associated with the risk of 
developing moderate­to­severe asthma regulate mucin 
production.
In this study, we identified 21 previously reported 
signals as being associated with asthma, including some 
previously associated with asthma that is severe or 
difficult to treat: RAD50 and HLA-DR/HLA-DQ,25 and 
17q21 (ORMDL3/GSDMB/ZPB2).19 Using eQTL analyses, 
we identified candidate causal genes for moderate­to­
severe asthma; however, the level of evidence for each 
potential candidate gene based on linkage disequilibrium 
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Figure 4: rs11603634 is an eQTL for MUC5AC in bronchial epithelial brush samples and MUC5AC mRNA expression is increased in bronchial epithelial cells 
from severe asthma patients
 (A) MUC5AC mRNA expression stratified by rs11602802 genotype. The boxes show the mean and SD and the whiskers show the IQR for each genotype. Generated 
from bronchial epithelial brush samples (n=117) collected as part of the U-BIOPRED study. rs11603634 was not directly genotyped, so the proxy rs11602802 was used. 
The rs11603634 asthma risk allele, G, is correlated with rs11602802, A, allele. (B) mRNA expression of MUC5AC in the GSE43696 dataset.41 Boxes showing the median 
and IQR, and the whiskers showing the minimum and maximum data, stratified by subject group. Bronchial epithelial brush samples were from controls (n=20), and 
patients with mild or moderate (n=50) and severe (n=38) asthma from the GSE43696 dataset and GC-RMA data for MUC5AC. MUC5AC levels were significantly higher 
in patients with severe asthma than in controls. (C) mRNA expression of MUC5AC in the GSE8980942 dataset. The boxes show the median and IQR, and the whiskers 
showing the minimum and maximum data, stratified by subject group. Bronchial epithelial brush samples were from controls (n=18), and patients with mild (n=14), 
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higher in patients with severe asthma than in controls. More details of datasets and analyses are in the appendix. eQTL=expression quantitative trait loci. 
GC-RMA=GeneChip robust multi-array average. U-BIOPRED=Unbiased BIOmarkers in PREDiction of respiratory disease outcomes. *p<0·05 by Kruskal-Wallace test.
For NCBI website see 
https://www.ncbi.nlm.nih.gov/
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with sentinel SNP, relevant tissue and cell type, and 
statistical significance varied from highly supportive to 
suggestive. Overall, these signals highlight the role of 
innate and adaptive immunity and type 2 inflammation 
in moderate­to­severe asthma including: CD247, which 
encodes T­cell receptor ζ; trans­acting T­cell specific 
transcription factor GATA­3 (GATA3), an important 
transcription factor in T cells; interleukin­18 receptor 1 
(IL18R1) and interleukin­1 receptor­like 1 (IL1RL1), 
receptors for key cytokines interleukin­18 and 
interlukin­33, respectively; thymic stromal lymphopoietin 
(TSLP), which drives type 2 inflammation; human 
leukocyte antigen genes that encode the major histo­
compatibility complex; transcription regulator protein 
BACH2 (BACH2), a transcriptional regulator in type 2 
inflammation; interleukin­33 (IL33), an innate cytokine; 
and signal transducer and activator of transcription 6 
(STAT6), a signalling molecule down stream of 
interleukin 4 and 13, which are drivers of type 2 
inflammation. The other genes identified highlight 
roles in homoeostasis of airway cells, including D­2­
hydroxyglutarate dehydrogenase (D2HGDH), which 
regulates α­ketoglutarate concentrations, influ encing 
histone and DNA methylation;49 sodium/hydrogen ex­
changer 2 (SLC9A2), a sodium­hydrogen exchanger 
involved in the regulation of cell pH and volume;50 
inhibitor of growth protein 5 (ING5), a transcription 
factor involved in epithelial to mesenchymal transition;51 
DNA repair protein RAD50 (RAD50), which is involved 
in DNA double­strand break repair; solute carrier family 
22 member 5 (SLC22A5), an organic cation trans­
porter with a role in epithelial cells; protein CLEC16A 
(CLEC16A), a regulator of autophagy;52 gasdermin­B 
(GSDMB), which is linked with airway smooth­muscle 
contraction;53 and  ORM1­like protein 3 (ORMDL3), 
which is linked with airway remodelling.54 
This is the first report, to our knowledge, of the 
MUC5AC locus being specifically associated with 
increased susceptibility to development of moderate­to­
severe asthma in a genome­wide association study. We 
showed this association in both stages 1 and 2 of our 
investigation, and in our meta­analyses; however, the 
higher severity of asthma in the cases (and associated 
power) in stage 1 than among those in stage 2 could 
explain the different significance levels between the 
stages—ie, cases in stage 1 had lower lung function than 
those in stage 2 and reported higher use of oral 
corticosteroids than those in stage 2. The proportion of 
cases with allergic comorbidities (allergic rhinitis or 
eczema, or both) or smoking history did not differ 
significantly between stages 1 and 2. The association 
between the asthma risk allele (G) of rs11603634 and 
increased concentrations of MUC5AC mRNA in 
bronchial epithelial brush samples, and the predicted 
effect on FOXA transcription factors provide putative 
mechanisms because FOXA2 regulates mucin­5AC 
(MUC5AC) production.55 We found this eQTL association 
to be the most significant for MUC5AC in the bronchial 
epithelial cell dataset. This signal of moderate­to­severe 
asthma has also previously been identified as associated 
with pulmonary fibrosis (proxy rs4077759, r²=0·42);48 
however, rs11603634 reported in our study and 
rs35705950 (the main idiopathic pulmonary fibrosis 
signal) are not in linkage disequilibrium (r²=0·01), 
suggesting distinct signals. Similarly, the signal we 
reported is independent from that reported (rs1132440) 
in a candidate gene study for asthma.56 We also identified 
an association between rs11603634 on MUC5B mRNA 
levels in bronchial epithelial brush samples, with carriers 
of risk alleles having lower concentrations than those 
who are not carriers, although this association did not 
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Figure 5: rs560026225 is an eQTL for KIAA1109 in lung tissue and KIAA1109 mRNA expression levels in 
bronchial epithelial cells from asthma patients
(A) rs560026225 asthma risk allele, GATT, correlated with the rs17454584, G, allele. Data are for KIAA1109 expression 
for each recruitment centre,35 stratified by rs17454584 genotype. The boxes show the mean and SD and whiskers 
show the IQR for each genotype. Non-tumour lung tissue was isolated from 1110 individuals who had undergone lung 
resection across three centres to generate the eQTL dataset. rs560026225 was not directly genotyped, so rs17454584 
was used as a proxy. (B) KIAA1109 expression levels in bronchial epithelial cells from asthma patients from the 
GSE43696 dataset.41 The boxes show the median and IQR, and whiskers the minimum and maximum data, stratified 
by subject group. Bronchial epithelial brush samples were from controls (n=20), and patients with mild or moderate 
(n=50) and severe (n=38) asthma in the GSE43696 dataset, and GC-RMA data for KIAA1109. No significant 
differences in KIAA1109 expression levels between groups were observed (Kruskal-Wallace test). (C) KIAA1109 
expression levels in bronchial epithelial cells from asthma patients from the GSE89809 dataset.42 The boxes show the 
median and IQR, and whiskers the minimum and maximum data, stratified by subject group. Bronchial epithelial 
brush samples were from controls (n=18), and patients with mild (n=14), moderate (n=13), and severe (n=11) asthma 
from the GSE89809 dataset, and GC-RMA data for KIA1109. No significant differences in KIAA1109 expression levels 
between groups were observed. See appendix for more details of datasets and analyses. eQTL=expression quantitative 
trait loci.  GC-RMA=GeneChip robust multi-array average.
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meet our significance threshold. MUC5AC protein 
concentrations are increased in the sputum of patients 
with asthma during exacerbations compared with 
patients with stable asthma and controls, whereas 
concentrations of mucin­5B (MUC5B) are decreased 
among patients with asthma—ie, alterations in the ratio 
of MUC5AC to MUC5B are a feature of asthma.57 This 
altered ratio of MUC5AC to MUC5B in asthma might be 
partially explained by the opposite effect of our novel 
asthma risk allele (G) of rs11603634 on MUC5AC and 
MUC5B production. MUC5AC has pathogenic roles and 
has been linked to airway hyper­responsiveness and 
mucus plugging during exacerbation.58 MUC5AC 
deficient mice develop allergic airway disease; however, 
the severity and abundance of mucus plugging is 
attenuated.59 Loss of MUC5B in a mouse knock­out study 
led to airway inflammation, suggesting a role in 
homoeostasis.60 Overall, these data suggest targeting of 
specific mucins could be a therapeutic opportunity for 
moderate­to­severe asthma.
The KIAA1109 (rs72687036) novel signal we identified 
has previously been associated with self­reported allergy21 
and allergic sensitisation,22 type 1 diabetes,61 ulcerative 
colitis,62 mean platelet volume,47 and with allergic disease 
(asthma, hayfever, allergic rhinitis, or eczema).23 The 
region is rich in candidate genes (eg, IL2 and IL21); 
however, our eQTL data suggest that the potential causal 
gene is KIAA1109. Little is known about KIAA1109. Mice 
deficient in KIAA1109 have preweaning lethality 
(International Mouse Phenotyping Consortium) and a 
suggested role in synaptic vesicle recycling in Drosophila 
has been identified.63
The third novel signal we identified, rs1090584 in 
GATA3, asthma risk allele C, is also associated with 
rheumatoid arthritis (proxy rs3824660; r²=0·86)64 and 
increased concentrations of blood eosinophils,47 a known 
effector cell in asthma. This signal has been associated 
with allergic disease (asthma, hayfever, allergic rhinitis, or 
eczema).23 The rs1090584 signal in GATA3 identified in 
this study is independent to those previously described for 
asthma, including rs10508372 in Japanese individuals,15 
rs2589561 in European or multi­ancestry individuals,11 and 
rs12413578 in European individuals.5 The second signal in 
GATA3 (rs61840192) we report is in linkage disequilibrium 
with rs12413578 and rs2589561 (r²=0·16). These data 
suggest that multiple genetic signals within the GATA3 
locus might contribute to asthma. We identified potential 
effects of rs1090584 on USF1 and USF2 in airway cells; 
however, we did not identify an eQTL association. USF1 is 
important in regulating GATA family genes, including 
GATA5.65 GATA3 is a transcriptional regulator associated 
with differentiation—eg, in type­2 innate lymphoid cell 
differentiation,66 an effector cell in type 2 inflammation.
We also investigated all previously reported asthma 
signals to date, with general replication of previous 
results. The previously described signals that did not 
replicate in our dataset were associated with a specific 
asthma phenotype (eg, PDE4D and mild­to­moderate 
childhood asthma with bronchial hyper­responsiveness16) 
or were reported in people of non­European ancestry (eg, 
NOTCH415). The effect sizes for previously described 
asthma signals in stage 1 of this moderate­to­severe 
asthma cohort (OR range 1·08–1·24) are comparable 
with those reported in large studies of asthma.5,11 
Similarly, we investigated allergic disease signals 
identified in two large genome­wide association 
studies,23,24 and found a large proportion of these signals 
were associated with moderate­to­severe asthma; how­
ever, our case­control design used moderate­to­severe 
asthma cases and controls excluding individuals with 
asthma, rhinitis, eczema, and allergy diagnosed by a 
doctor, and so the ability to identify genetic signals 
associated with allergic comorbidities in the asthma 
population will be enhanced compared with these 
previous studies.
Our study had several limitations. Regarding the 
design of the study, we considered alternative approaches 
when planning the analysis, such as using patients with 
mild asthma as the control group. However, we opted to 
compare patients with moderate­to­severe asthma with 
healthy controls in the initial discovery analysis because 
we felt that this comparison would minimise the risk of 
misclassification between mild and moderate asthma 
and so be a more powerful strategy for a genetic study. 
We included a large genome­wide association study of 
asthma5 to specifically address the issue of specificity of 
the signals we found in our cohort to moderate­to­severe 
asthma. Cases in stage 1 have more severe asthma than 
those in stage 2 because patients from GASP and 
U­BIOPRED in stage 1 were predominantly recruited 
from secondary care. This potential difference between 
cases in stage 1 and 2 might have contributed to the 
attenuated association with, for example, the MUC5AC 
signal in the stage 2 cohort; however, this difference also 
potentially provided additional power for stage 1. We also 
acknowledge that we defined asthma severity on the 
basis of medication use alone and additional measures 
including symptoms, exacerbation frequency, and other 
markers would have enhanced the definition, although 
these data were not available. Importantly, all cases in 
our analyses required a doctor diagnosis of asthma for 
inclusion before stratification on the basis of medication. 
Severe asthma is defined by the requirement for high 
dose of inhaled corticosteroid or maintenance oral 
corticosteroid, with persistent poor control or a high risk 
of developing poor control if these therapies are stepped 
down. Similarly, the Global Initiative for Asthma 
treatment steps are used as surrogates of severity. Thus, 
using the treatment step as a measure of severity is in 
keeping with current guidelines and has the advantage 
that it provides maximum sample sizes because 
medication data are available for a greater number of 
patients than, for instance, symptom scores. Additionally, 
for cases who were prescribed oral corticosteroids, we 
For the International Mouse 
Phenotyping Consortium 
website see http://www.
mousephenotype.org
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did not undertake individual case reviews to exclude the 
possibility that some patients might have been receiving 
oral corticosteroids for other comorbid conditions, and 
we did not record additional information on current 
asthma control or exacerbation frequency, which would 
have been informative. Advances in imputation mean 
that the widely used threshold for genome­wide 
significance of a p value of less than 5 × 10–⁸, historically 
defined on the basis of 1 million independent tests, 
could be considered too lenient for an analysis of 
33 million SNPs (representing >1 million independent 
tests). Had we applied a threshold p value of less than 
5 × 10–⁹, recommended as an appropriate threshold for 
studies of whole­genome sequence data from European 
populations,67 the signals at GATA3 (p=1·76 × 10–¹⁰) and 
KIAA1109 (p=3·06 × 10–⁹) would still have been 
significant. Overall, the MUC5AC signal was weaker in 
terms of significance compared with other signals 
identified—eg, in stage 2, this signal only met nominal 
significance not Bonferroni correction and was just 
within the threshold for genome­wide significance in 
the meta­analysis. Finally, asthma is a complex disease 
involving both genetic and environ mental influences 
and we have not formally assessed the role of the 
environment, which could be critical for the development 
of more severe asthma. Accumulating data suggest a 
role for several factors in the development of severe 
disease (eg, comorbidities such as atopic dermatitis in 
severe asthma68 and environmental or epigenetic 
mechanisms69) but further work is needed.
In summary, to our knowledge, this is the largest 
genome­wide association study of moderate­to­severe 
asthma published to date, in which we have identified 
that the genetic architecture of moderate­to­severe 
asthma is similar to mild disease, three novel genome­
wide significant associations, and potential candidate 
causal genes underlying these signals. These findings 
provide new understanding for this difficult to treat 
population and adds to the accumulating evidence that 
strategies to target mucins might have therapeutic value. 
Similarly, our findings add to evidence that targeting type 
2 inflammation in asthma could be particularly useful 
for moderate­to­severe asthma, potentially in carriers of 
genetic variants in genes of relevance to innate or 
adaptive immunity.
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